On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of kanker paru conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumor cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb ngungkabkeun yén perusahaan parantos ngalebetkeun aplikasi Opdivo pikeun pengobatan indikasi kanker paru-paru ka FDA sareng administrasi farmasi EU. Tangtosna, perusahaan Squibb anu ambisius sacara alami henteu ngan ukur wareg ku kanker paru-paru sareng melanoma. Nyatana, Squibb ayeuna ngalaksanakeun langkung ti 35 panilitian ngeunaan Opdivo nyalira atanapi digabungkeun sareng obat-obatan sanés pikeun ngubaran jinis tumor anu béda. Numutkeun analis, penjualan kahareup Opdivo bakal ngahontal saluhur 5 milyar dolar AS.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Laporan Inggris lengkep:
Bristol-Myers Squibb's ($ BMY) standout immuno-o ncology drug nivolumab, disatujuan bulan panungtungan salaku Opdivo, nyetak kasuksésan resounding dina percobaan kanker paru-tahap telat, bolstering ekspektasi jualan keur pengobatan neering pioner.
Dina ulikan 272-pasien ngadu Opdivo ngalawan docetaxel pembunuh kanker standar, demo ubar Bristol-Myers nunjukkeun kasalametan umum anu unggul dibandingkeun sareng panangan kontrol anu pencét titik akhir utami sateuacan jadwal, ngarah data uji coba nyarankeun panitia. pangajaran ditungtungan awal. Bristol-Myers ayeuna ngondang pasien dina grup docetaxel pikeun milih Opdivo ngaliwatan studi ekstensi labél kabuka.
Pangobatan Bristol-Myers dirancang pikeun ngagaleuhkeun serangan sistem imun kana tumor ku cara ngahalangan jalur anu disebut PD-1, anu, ditinggalkeun henteu dicentang, ngamungkinkeun sél kanker lolos tanpa kadeteksi ku pertahanan alami awak. Sapertos Keytruda anu sami sareng Merck ($ MRK), Opdivo nampi persetujuan FDA taun ka tukang salaku pangobatan pikeun melanoma, tapi ubar Bristol-Myers nangtung nyalira dina kanker paru-paru, sabab kasuksésan klinis pang anyarna nandaan pertama kalina inhibitor PD-1 parantos ngagambar a kaunggulan survival ngalawan kasakit, ceuk parusahaan.
Opdivo’s particular promise in kanker paru sél non-leutik has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers parantos ngintunkeun aplikasi kanker paru-paru di AS sareng Éropa pikeun Opdivo dina kanker paru-paru, ngarep-ngarep ngalegaan pamakean narkoba dina ahir taun ieu.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, kanker sirah sareng beuheung, glioblastoma, Non-Hodgkin lymphoma and other cancers.
